Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
-
A herd stop: Train kills 3 rare bison in Poland
-
Vietnam, Russia to sign energy deal: Hanoi
-
American Gumberg triumphs in Hainan for second DP World Tour win
-
South Africa clinch 19-run win over New Zealand in fourth T20
-
Iran threatens Middle East infrastructure after Trump ultimatum
-
French elect mayors in key cities including Paris
-
'They beat us with whips': Sudan RSF detainees tell of horrors in El-Fasher
-
Australia's Hannah Green wins historic third tournament in a row
-
China's premier vows to expand global 'trade pie': state media
-
Belgium commemorates Brussels attacks 10 years on
-
Sri Lanka raises fuel prices by 25 percent as war bites
-
Rights groups fear use of arrest to stifle free speech in Pakistan
-
Iranian missiles sow panic, destruction in Israeli towns
-
Damaged Russian tanker to be towed to Libya: state-owned company
-
Gilgeous-Alexander scores 40, LeBron breaks NBA appearance record
-
Cuba hit by second nationwide blackout in a week
-
BTS draws over 100,000 fans to Seoul comeback concert: label
-
US-China 'Board of Trade' may help ties but experts flag market worries
-
Sinner, defending champ Mensik advance to third round at Miami Open
-
Iran missile strikes wound over 100 in two south Israel towns
-
Shai hits 40 as Thunder win despite NBA melee with four ejected
-
Records shattered as US heatwave moves eastward
-
Iran missiles hit southern Israel, injuring more than 100
-
LeBron James breaks record for most NBA games played
-
'Perfect' PSG sweep past Nice to reclaim top spot in Ligue 1
-
Japan coach says Asian Cup crown 'well-deserved' for inspirational team
-
PSG sweep past Nice to reclaim top spot in Ligue 1
-
Robert Mueller, ex-FBI chief who led Trump-Russia probe, dead at 81
-
Milan move to within five points of Serie A leaders Inter
-
Duplantis masterclass as Kerr and record-setter Ehammer shine
-
Rosenior urges Chelsea to 'forget the noise' after damaging loss
-
Marquez ambushed Di Giannantonio to win Brazil sprint
-
Sweden's Duplantis wins fourth world indoor pole vault title
-
Liverpool, Chelsea slip up in Champions League race
-
WHO sends first overland convoy from emergencies hub to Beirut
-
Everton rub salt in Chelsea wounds as Champions League race tightens
-
Coach Mignoni returns but Toulon crash to Stade Francais
-
Robert Mueller, ex-FBI chief who led Trump-Russia inquiry, dead at 81
-
Sinner and Pegula advance to third round at Miami Open
-
Britain's Kerr outsprints Hocker for world indoor 3,000m gold
-
Kane backs Tuchel's call to rest him from England friendly
-
NBA fines 76ers' Drummond, Magic's Suggs $25,000 each
-
Switzerland's Ehammer sets indoor heptathlon world record
-
Pogacar 'relieved' by Milan-San Remo triumph, gunning to complete Monument set
-
World Athletics decision to hand Asia two world indoors 'strategic' - Coe
-
Trump threatens to use ICE agents for airport security control
-
Kane moves closer to goals record as Bayern sink Union
-
Pogacar ends long wait for Milan-San Remo glory after edging epic
-
US says 'took out' Iran base threatening blocked Hormuz oil route
-
Di Giannantonio takes Brazil MotoGP pole ahead of Bezzecchi, Marquez
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its first quarter of fiscal 2026, after the market close on Thursday, November 13, 2025. The Company has scheduled a conference call and webcast that same day, Thursday, November 13, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Thursday, November 13, 2025, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 240426.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53111, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until November 27, 2025, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53111.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD) and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering our medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
P.Martin--AMWN
